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ABSTRACT
Methylated xanthines (methylxanthines) are available from a significant number of different botanical
species. They are ordinarily included in daily diet, in many extremely common beverages and foods.
Caffeine, theophylline and theobromine are the main methylxanthines available from natural sources. The
supposedly relatively low toxicity of methylxanthines, combined with the many beneficial effects that
have been attributed to these compounds through time, generated a justified attention and a very prolific
ground for dedicated scientific reports. Methylxanthines have been widely used as therapeutical tools, in
an intriguing range of medicinal scopes. In fact, methylxanthines have been/were medically used as
Central Nervous System stimulants, bronchodilators, coronary dilators, diuretics and anti-cancer adjuvant
treatments. Other than these applications, methylxanthines have also been hinted to hold other beneficial
health effects, namely regarding neurodegenerative diseases, cardioprotection, diabetes and fertility.
However, it seems now consensual that toxicity concerns related to methylxanthine consumption and/or
therapeutic use should not be dismissed. Taking all the knowledge and expectations on the potential of
methylxanthines into account, we propose a systematic look at the past and future of methylxanthine
pharmacologic applications, discussing all the promise and anticipating possible constraints. Anyways,







There are compelling historical and anthropological evidences
of methylxanthines being included in human diet for a very
long time. Nowadays, the consumption of products containing
methylxanthines is undeniably widespread and very common
in human populations. And other than the more traditional
dietary sources of methylxanthines, like coffee, tea or chocolate,
there are other methylxanthine-containing products that are
gathering increased popularity, but also raising some concerns.
That is the case of energetic drinks and food supplements,
which often contain significantly increased amounts of methyl-
xanthines with regard to the traditional sources. Caffeine is the
more thoroughly studied methylxanthine so far, probably due
to the high prevalence of its consumption in present diet. Meth-
ylxanthine therapeutic properties have been reported in a num-
ber of pathologic contexts. They have been used in medicine
for decades in different medical scopes, namely respiratory
disease (Lam and Newhouse 1990), cardiovascular disease
(Batterman et al. 1959) and cancer (Hayashi et al. 2005; Kimura
et al. 2009). However, the mechanisms underlying the benefi-
cial action of methylxanthines in such conditions have not
always been clarified.
Herein, we discuss the historical relevance of methylxan-
thine use in medicine and the emerging contexts where they
have shown promise and were hinted as potential therapeutical
tools. The current therapeutical uses in medicine are summa-
rized in Fig. 1, and will be discussed in later sections. The
molecular mechanisms involved in the beneficial effects of
methylxanthines in various scopes will also be discussed.
2. Methylxanthine chemistry and analysis
Methylxanthines are heterocyclic organic compounds that are
methylated derivatives of xanthine, therefore comprising coupled
pyrimidinedione and imidazole rings (Talik, Krzek, and Ekiert
2012). Caffeine (1,3,7-trimethylxanthine), theophylline (1,3-
dimethylxanthine) and theobromine (3,7-dimethylxanthine) are
the methylxanthines most frequently available from natural sour-
ces (Fig. 2). They differ in the number (caffeine has three, the
others two) and position of N-CH3 groups. Paraxanthine
(1,7-dimethylxanthine), another relevant methylxanthine, is not
produced by plants but appears as a product of caffeine metabo-
lism, namely in humans (Nehlig 2015). Methylxanthines are pres-
ent in nearly 100 species of 13 orders of the Plant Kingdom
(Ashihara and Crozier 1999; Ashihara and Suzuki 2004), includ-
ing tea (Camellia sinensis L.), coffee (Coffea sp.) and cacao (Theo-
broma cacao L.). Caffeine is present in Coffea species (0.4 to 2.4%
dry weight (Mazzafera and Carvalho 1991)) and in the tea plants
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Camellia sinensis, Camellia assamica and Camellia taliensis (2–
3%) (Ashihara, Sano, and Crozier 2008). Theobromine may be
present in some Camellia species, although Theobroma cacao is
normally reported as its major natural source (Ashihara, Sano,
and Crozier 2008). Theophylline is abundant in tea species, but is
also present in trace amounts in cocoa and coffee beans (Barnes
2013). Paullinia sp., Cola sp. and Citrus sp. also contain methyl-
xanthines (Atawodi et al. 2007; Baumann, Schulthess, and H€anni
1995; Kretschmar and Baumann 1999; Weckerle, Stutz, and Bau-
mann 2003). Regarding human consumption through dietary
products, caffeine and theophylline (typically at much lower
amounts) may be ingested in coffee, tea, cola beverages and choc-
olate (Stavric 1988a), although tea contains less caffeine than cof-
fee (Gilbert et al. 1976). Tea and chocolate should account for
most theobromine intake through diet (Stavric 1988c).
Methylxanthines have been proposed to have many systemic
effects in humans. Nevertheless, the mechanisms by which meth-
ylxanthines exert their biological effects are not fully understood.
Nonetheless, some studies tried to establish chemical structure-
bioactivity relationships for methylxanthines, evaluating the
extent of their interaction with particular molecular targets (see
(Monteiro et al. 2016) for a detailed review). Classically there are
four mechanisms of action proposed for methylxanthine
physiological action. These are adenosine receptors antagonism,
phosphodiesterase inhibition, modulation of the action of recep-
tors and regulation of intracellular calcium levels through ryano-
dine channels (Chen and Chern 2011; Choi et al. 1988; Dent et al.
1994; Liu and Meissner 1997; McPherson et al. 1991; Tazzeo et al.
2012) (Table 1). Antagonism of adenosine receptors is thought to
be themainmechanism ofmethylxanthine action, and their activ-
ity is thought to be exerted preferably by modulation of A1 and
A2A receptors, which are inhibited in the mM range (Fredholm
et al. 1999).
There are many available technical approaches to extract,
identify and quantify these compounds in different kinds of sam-
ples (food, beverages and even biological fluids) and many of
those techniques also aim the simultaneous determination of the
main methylxanthines (caffeine, theobromine and theophylline)
(Fig. 3). They commonly involve some kind of pre-treatment
protocols to eliminate unwanted matrix interferences, usually
involving liquid-liquid (Begas et al. 2007; Bendriss, Markoglou,
and Wainer 2000; El-Yazigi et al. 1999; Krul and Hageman 1998;
Newton et al. 1981b; Van Soeren et al. 1996) or solid-phase
extraction (Emara 2004; Fenske 2006; Georga, Samanidou, and
Papadoyannis 2000; Setchell et al. 1987; Srdjenovic et al. 2008).
Methylxanthine extraction is usually based in sequential aqueous
extraction, followed by organic extraction (with dimethyl chlo-
ride, chloroform, methanol or n-hexane (Belscak et al. 2009;
Caudle, Gu, and Bell 2001; Hulbert et al. 1998; Unachukwu et al.
2010; Xia, Ni, and Kokot 2013)). Liquid chromatography (LC),
namely reversed-phase high-performance liquid chromatogra-
phy (RP-HPLC) has been the choice normally used for methyl-
xanthine separation and determination. Low pressure
chromatography was also recently proposed as an analytical
alternative for methylxanthine separation and screening in sam-
ples (Santos and Rangel 2012). Methylxanthine identification
and quantification is commonly spectrophotometrically per-
formed (by DAD or UV, at or about 273 nm (Adams, Vande-
mark, and Schmidt 1976; Seeram et al. 2006)). HPLC coupled to
mass spectrometry methods represent a more incisive recent
resource, allowing acquiring structural information and unequiv-
ocal identification of the compounds (Bech and Bossi 2015;
Huck, Guggenbichler, and Bonn 2005; Ptolemy et al. 2010).
3. Methylxanthine pharmacokinetics
Many beneficial physiological effects have been attributed to
methylxanthines, and they have even established themselves as
valid therapeutic tools in some contexts. These health and
pharmacological effects should substantially depend on the bio-
availability and biotransformation of methylxanthines in the
organism. Therefore, a growing number of studies were made
in order to determine pharmacokinetic parameters for every
one of the main natural methylxanthines.
Methylxanthines (caffeine, theophylline, theobromine, and par-
axanthine) are thought to distribute through all body fluids and to
cross all biological membranes upon administration to both ani-
mals and humans. Nevertheless, after ingestion or administration,
methylxanthines are not expected to accumulate in organs or tis-
sues and, are posteriorly metabolized in the liver (Arnaud 2011).
A study aiming at determining pharmacokinetic parameters
of caffeine, theophylline, theobromine and also paraxanthine in
Figure 1. Chronology of methylxanthine medical use.
Figure 2. Chemical structures of natural methylxanthines.
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the same individuals, for direct comparison purposes (Lelo
et al. 1986) revealed that caffeine and paraxanthine on one
hand, and theophylline and theobromine on the other, had
similar pharmacokinetic profiles, namely concerning the calcu-
lated half-lives and respective plasma clearances. Caffeine and
paraxanthine displayed shorter half-lives (4.1 and 3.1 h, respec-
tively) comparatively to for theophylline and theobromine (6.2
and 7.2 h) and higher plasma clearances (2.07 and 2.20 mL
min¡1kg¡1, respectively compared to 0.93 and 1.20 mL
min¡1kg¡1, for theophylline and theobromine). Therefore, sys-
temic effects of theophylline and theobromine, which remain-
ing longer in the body, should be expected to be maintained for
a longer period of time. As for the volume of distribution at
steady state, theophylline had a lower value (0.44 L/kg¡1) as
compared to the others (0.63 – 0.72 L/kg¡1).
Caffeine is rapidly and completely absorbed in humans at the
gastrointestinal level, mainly at small intestine, but also at the
stomach (20%) (Chvasta and Cooke 1971). Following a 5 mg/kg
oral administration, plasma peak concentration was shown to be
attained at 29.8 § 8.1 min.kg, with a peak plasma concentration
of 10.0 § 1.0 mg/mL (Blanchard and Sawers 1983), a concentra-
tion that should raise limited action on caffeine molecular targets
(<IC50). However, a more recent study predicted a maximal
plasma concentration of 1335 ng/ml after consumption of one
cup of coffee (about 80 mg of caffeine), for which expected sys-
temic effect should be even lower (Zandvliet et al. 2005). Other
studies reported maximum concentrations in the same range
after caffeine intake of about 100 mg (Perera, Gross, and McLa-
chlan 2010; Teekachunhatean et al. 2013). Interestingly, adminis-
tration route does not significantly change these parameters in
the case of intravenous administration (Blanchard and Sawers
1983; Newton et al. 1981a). However, enema exposure lowers
relative bioavailability of caffeine by about 3.5 times with regard
to oral consumption (Teekachunhatean et al. 2013) while inhala-
tion lowers it to 60% (Zandvliet et al. 2005). These studies show
that caffeine bioavailability is dependent of the administration
route and thus, it should be taken in consideration when discus-
sing its pharmacological potential. Moreover, studies suggested
that the rate of consumption, as well as the temperature of bever-
age and vehicle (coffee versus energy drink), had little impact on
caffeine pharmacokinetics (White et al. 2016) illustrating that
the stability of the compound is independent of those factors.
Caffeine first pass effect (concentration reduction before reach-
ing systemic circulation) is thought to be minimal (Yesair, Branf-
man, and Callahan 1984) and elimination was proposed to be a
first-order process (Arnaud 1993; Newton et al. 1981a) and is
described by a one-compartment open model system in the dose
range of intake of 2 – 10 mg/kg (Blanchard and Sawers 1983;
Bonati et al. 1982; Newton et al. 1981a). Another study proposed
linear pharmacokinetics for caffeine in intakes between 70 and
100 mg (about a cup of coffee), while for higher doses (between
250 and 500 mg) the kinetics were non-linear and half-life was
prolonged, what could insinuate prolonged systemic/pharmaco-
logical effects (Kaplan et al. 1997). Interindividual significant
variations in caffeine half-lives (2.3 – 9.9 h) should indicate idio-
syncratic factors determining elimination (Blanchard and Sawers
1983). For instance, the elimination of methylxanthines (namely
caffeine and theophylline) was proposed as being considerably
slower in the neonate, with caffeine being excreted in the urine
of newborns mainly unchanged (85%, while 2% in adults) (Ara-
nda, Turmen, and Sasyniuk 1980). This suggests that fetal and
neonatal exposure could increase the susceptibility to caffeine
systemic effects, and this concern will in fact be addressed in a
later section of this review.
As for caffeine, theophylline is also rapidly and completely
absorbed (Hendeles and Weinberger 1983; Ogilvie 1978; Yesair,
Branfman, and Callahan 1984), with the major part of the
absorption taking place before the jejunum (Brouwers et al.
2005). Absorption of theophylline was proposed to follow first-
order kinetics, at least following oral administration in the 125
– 500 mg range (Rovei, Chanoine, and Strolin Benedetti 1982).
Table 1. Main mechanisms of action of methylxanthines and available parameters suggesting physiological concentrations of interest.
Methylxanthine physiological mechanism Methylxanthine Effective concentrations (mM) References
Antagonism of adenosine receptorsa Caffeine 55 (A1) and 50 (A2A) (Daly et al. 1985)
Theophylline 14a (Daly et al. 1985)
Phosphodiesterase inhibitionb Caffeine 1000 (Butcher and Sutherland 1962)
Theophylline 200-300 (Butcher and Sutherland 1962)
Theobromine 1000 (Butcher and Sutherland 1962)
GABA receptor modulation Caffeine 500b (Shi, Padgett, and Daly 2003)
Activation of ryanodine-sensitive calcium channelsb Caffeine 1760 or 6000 (Gaburjakova and Gaburjakova 2014)
(McPherson et al. 1991)
adissociation constant values; bIC50
Figure 3. General methods for methylxanthine analysis.
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Accumulation of theophylline in brain, liver, muscle, and adi-
pose tissue is lower than that of caffeine (Sta

hle 1991), probably
reflecting its lower lipophilicity. Theophylline pharmacokinet-
ics were accessed in asthmatic patients, with reported peak
plasma concentration of 8.4 § 1.7 mg/L, attained at 2.2 § 0.8 h
after oral ingestion of a 5 mg/kg dose (Becker et al. 1984). Other
authors reported peak plasma theophylline levels of 7 mg/L
after a single oral dose of 250 mg (French and Mildon 1979).
Within therapeutic range plasma levels, first-order kinetics are
assumed to apply to theophylline and, thus, a one-compart-
ment model or a model-independent approach is routinely
used for dose adjustments (Butts, Secrest, and Berger 1991).
However, theophylline frequently exhibits nonlinear pharma-
cokinetics, as suggested from studies in animal models
(El-Yazigi and Sawchukx 1981; Teunissen et al. 1985), young
children (Ginchansky and Weinberger 1977; Sarrazin et al.
1980; Weinberger and Ginchansky 1977), and patients treated
for obstructive pulmonary diseases (Butts, Secrest, and Berger
1991). Interindividual variability also seems to occur regarding
theophylline clearance (Fleetham et al. 1981), which was sug-
gested to be influenced by age, sex, diet, liver function, and also
external influences such as smoking (French and Mildon 1979;
Ogilvie 1978). This is why the recommended standard pharma-
cological doses should be seen as mere guidelines and approxi-
mations, and physicians could begin by prescribing smaller
doses and warily increase from there at tolerated intervals
(Ogilvie 1978).
Theobromine pharmacokinetics have not been subject of as
many reports as the other main natural methylxanthines. Any-
way, it is interesting that the absorption when ingested in choco-
late (80%) is lower than when ingested in a solution, what is
thought to be related with interaction with other chocolate com-
ponents (Shively et al. 1985). Theobromine was found in all fluids
(including plasma, saliva, and breast milk) 2–3 h after ingestion of
an oral dose of chocolate containing 240 mg by nursing mothers,
with concentrations peaking from 3.7 to 8.2 mg/L (Resman, Blu-
menthal, and Jusko 1977). Another study reported that an oral
dose of chocolate containing 370 mg of theobromine produced a
plasma peak concentration of 8.05 mg/mL after 2 h (Mumford
et al. 1996). Another reported peak plasma value of 9.8§ 0.8 mg/
L, occurred 2.1 § 0.6 hours after drug ingestion (Simons et al.
1985). Studies reported theobromine half-lives of 7.1 § 2.1 h (a
dose of 240 mg of theobromine in nursing mothers) (Resman,
Blumenthal, and Jusko 1977), 6.1§ 0.7 h (after a single oral dose
of 6 mg/kg normal male volunteers) (Drouillard, Vesell, and
Dvorchik 1978), 9.28§ 0.7 h (10 mg/kg theobromine in healthy,
nonsmoking men) (Tarka et al. 1983), and 5.5§ 1,8 h (10 mg/kg
dose in young patients with asthma) (Simons et al. 1985). These
relatively high half-life values (comparing to caffeine, for instance)
should imply greater duration of action and longer intervals
between doses. Theobromine clearance was proposed to follow
first-order kinetics with a one-compartment open model (Tarka
et al. 1983).
Methylxanthines are mainly metabolized in the liver
(Arnaud 2011). Several demethylation processes may repre-
sent the first steps in the metabolism of caffeine (Stavric
1988a), as shown in Fig. 4. Caffeine is primarily metabolised
via oxidative demethylation by liver cytochrome P450 1A2
(CYP1A2) (Kot and Daniel 2008), and only less than 2% of
the ingested caffeine is excreted in human urine (Arnaud
2011). Caffeine may be in fact demethylated onto paraxan-
thine (84%), theobromine (12%) or theophylline (Nehlig
2015). These are further metabolized and then excreted in the
urine. The major caffeine-derived metabolites found in urine
are paraxanthine, 1-methylxanthine, 1,7-dimethyluric acid, 1-
methyluric acid, and 5-acetylamino-6-formylamino-3-meth-
yluracil (Begas et al. 2007). Urinary excretion of methylated
xanthines and uric acids was shown to take place within
24 hours upon coffee consumption, proving the rather fast
metabolism of caffeine in humans (Martınez-Lopez et al.
2014). Interindividual differences in caffeine metabolism are
explained by CYP1A2 polymorphisms (Grosso and Bracken
2005), and should determine differences in pharmacologic
responses to caffeine. The other major enzymes involved in
caffeine metabolism are N-acetyltransferase and xanthine oxi-
dase (Fenster et al. 1998). As for theophylline, it mainly
undergoes 8-hydroxylation to 1,3, dimethyluric acid (around
60–80%). N-demethylation to 1-methylxanthine (8–24%) or
to 3-methylxanthine (5–15%) being alternative routes (Fuhr
et al. 1993). For theobromine N3-demethylation accounted
for 58 § 7% and N7-demethylation for 27 § 6%, of its urinary
metabolites (Rodopoulos, H€ojvall, and Norman 1996). These
studies highlight that pharmacologic responses to methylxan-
thines are highly dependent of several factors that must be
taken in consideration, particularly idiosyncrasies that may
impact individual response, which depends on methylxan-
thine metabolism, excretion and bioavailability.
A second mechanism proposed to account for methylxanthine
physiologic activity is the inhibition of phosphodiesterases (Beavo
et al. 1970; Choi et al. 1988; Herman and Herman 2013), phos-
phodiesterase-4 (PDE4) in particular (Ruangkittisakul and
Figure 4. Demethylation processes that occur as the first steps in the metabolism
of caffeine (mostly metabolized to paraxanthine, shadowed path), and that origi-
nate other methylxanthines (thicker arrows, and in this case mean predominant
routes). Further metabolism involves oxidation to urates (Stavric 1988a).
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Ballanyi 2010; Sugimoto et al. 2014), halting the degradation and
therefore promoting cAMP concentration increase. Naturally
occurring methylxanthines are all considered relatively weak
competitive inhibitors of phosphodiesterases (Daly 2007), but
theophylline has a more potent action than caffeine (and theo-
bromine) at this level (Stavric 1988a).
Another mechanism proposed to elicit methylxanthine
mechanistic activity concerns the modulation of GABA recep-
tors. In fact, caffeine (Lopez et al. 1989) and theophylline (Sugi-
moto et al. 2001) were reported to modulate the ion transport
accomplished by these structures. Caffeine and theophylline
should act as antagonists or reverse agonists at benzodiazepine
sites, while also interacting with the picrotoxinin and GABA
sites (Roca, Schiller and, Farb 1988; Shi, Padgett, and Daly
2003).
The other mechanism classically related to methylxanthine
action is the stimulation of calcium release from intracellular
stores through ryanodine-sensitive calcium channels located in
the sarcoplasmic reticulum (Daly 2000; Gaburjakova and
Gaburjakova 2014; McPherson et al. 1991; M€uller and Daly
1993; Rousseau et al. 1988). Caffeine is a full agonist of the rya-
nodine receptors, prompting Ca2C transient fluxes (Kuemmerle
et al. 1994; Shi, Padgett, and Daly 2003; Shou et al. 2013), while
theophylline and theobromine are less effective in increasing
intracellular calcium elevation through this mechanism (M€uller
and Daly 1993). This mechanism may be in the genesis of caf-
feine’s pro-arrhythmic action, since it was suggested that it
may result from a caffeine-dependent shift in cardiac ryanodine
receptors luminal Ca2C activation threshold (Kong et al. 2008).
Activation of ryanodine receptors by caffeine may also contrib-
ute to its beneficial effects in cancer contexts (Mariot et al.
2000), but it should be kept in mind that it only occurs at sig-
nificantly high concentrations, at least in vitro.
Of these mechanisms proposed for the action of methylxan-
thines, adenosine receptor antagonism should be the more rele-
vant (Daly 2007; Fredholm 1985; Fredholm et al. 1999), since
physiological plasma concentrations achieved by dietary intake
(<100mM) should not be effective in interfering with the activ-
ity of phosphodiesterases and GABAA receptors, or ryanodine
receptors (Daly 2007; Fredholm et al. 1999; Marangos et al.
1979) (Table 1). Pharmacological doses (in mM concentration
range) may indeed prompt the inhibition of phosphodiesterases
(Beavo et al. 1970; Butcher and Sutherland 1962; Cardinali
1980; Nicholson, Jackman, and Wilke 1989), but the relevance
of the other mechanism proposed may be restricted by the
comparatively large effective concentrations required.
4. Methylxanthines as pharmacological tools
All natural methylxanthines have been attributed specific phar-
macological uses. The fact that such relevant biological effects
are combined with relatively low toxicity, makes methylxan-
thines very tempting and intriguing therapeutic prospects. Caf-
feine potently stimulates the Central Nervous System (CNS)
and respiratory system, while is very effective in cardiac stimu-
lation, coronary dilatation and smooth muscle relaxation.
Regarding theobromine, its most notable action would be as a
cardiac stimulant (Riksen, Smits, and Rongen 2011). It is
possible to rank the relative potency of each of the natural
methylxanthines in every of these contexts (Table 2).
Other than the therapeutic uses already established for
methylxanthines in medicine (a chronology is depicted in
Fig. 1), new contexts where they are hinted to hold positive out-
comes are being proposed. That has raised interest not only in
methylxanthines but also in methylxanthine-containing dietary
products, some of them very common. Regarding the two main
methylxanthine sources for which beneficial effects have been
recognized for more time, the rewarding effects of coffee and
tea consumption are well characterized. Coffee (and caffeine)
ingestion is known to propitiate an increase in energetic
arousal, an improvement in hedonic tone, an increase in self-
reported alertness, an improvement of psychomotor perfor-
mance and in concentration (Nehlig 2010a; Nehlig 2015; Rux-
ton 2008). However, at higher doses (>200 mg), caffeine may
cause anxiety and other unpleasant effects (Brice and Smith
2002; Childs and Wit 2006). As for tea, it has been proposed as
a promising agent for the prevention and treatment of several
human diseases, and some of the reported effects have been
related, at least in some degree, with methylxanthines profile
and total content (Carvalho et al. 2010; Jiao et al. 2015; Nunes
et al. 2014; Schuller et al. 2004). At least some of the beneficial
effects attributed to methylxanthines could be associated, at
least in part, with their high antioxidant capacity (Azam et al.
2003; Grucka-Mamczar et al. 2009; Leon-Carmona and Galano
2011). In the following subsections we discuss the methylxan-
thine pharmacological use or potential within the context of
selected health problems.
4.1. Respiratory disease
Methylxanthines have efficiently been therapeutically used in a
number of disease contexts. Respiratory disease should be,
however, the context in which methylxanthine medicinal use is
more familiar. Curiously, each of the three main natural meth-
ylxanthines, caffeine, theophylline and theobromine, has been
preferentially used in the treatment of specific different condi-
tions (apnea of prematurity, asthma and cough respectively).
The first therapeutic applications of methylxanthines were
discovered in the context of asthma treatment. The bronchodi-
latory effects attributed to methylxanthines in this context are
thought to be elicited by relaxation of human airway smooth
muscle, through inhibition of phosphodiesterases (Barnes
2005; Barnes 2013). Increase in cAMP levels would also inhibit
the activation of inflammatory cells (Barnes and Pauwels
1994). Adenosine receptor blockade has also been proposed as
a putative therapeutic mechanism in asthma treatment (Fozard
and McCarthy 2002; Russo, Arcidiacono, and Polosa 2006).
Table 2. Ranking methylxanthine effectiveness in different pharmacological con-









Skeletal Muscle Stimulation Caffeine>Theophylline>Theobromine
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Methylxanthines may also produce beneficial effects in bron-
chial asthma by chitinase inhibition (Tsirilakis et al. 2012).
These enzymes have been proposed to play a pivotal role in the
pathogenesis of the disease (Lee et al. 2014) and were found to
be overexpressed in the asthmatic lung (Rao et al. 2005).
Theophylline is considered a rather potent bronchodilator
(Stavric 1988a), and has been widely used in asthma context
for a long time now since it was introduced as a clinical treat-
ment for the condition in 1922 (Barnes 2013). Theophylline
appears to diffuse better in bronchial tissue than other methyl-
xanthines (van Zyl et al. 2008), and this should justify its pref-
erential use over the others. However, relatively high plasma
concentrations of theophylline (10–20 mg/L) are needed to
achieve bronchodilation effects comparable with those of b2-
agonists, and at doses that inhibit phosphodiesterases, however
several side effects may arise from the pharmacological use of
this methylxanthine (Barnes and Pauwels 1994; El-Bitar and
Boustany 2009). Currently, theophylline is recommended as an
additional bronchodilator if asthma remains difficult to control
after high doses of inhaled corticosteroids, plus long-acting
b2-agonists (Wilson, Gibson, and Coughlan 2000). Doxofylline
is another xanthine derivative that has also been proposed
to be an effective bronchodilator (Dini and Cogo 2001).
Doxofylline differs from theophylline by the presence of a diox-
olane group in position 7 (Goldstein and Chervinsky 2002).
Doxofylline has been reported to hold similar efficacy, along
with better tolerability profile than theophylline (Sankar,
Lodha, and Kabra 2008). This improved safety profile may
have to do with the absence of affinity towards adenosine
receptors (Cirillo, Barone, and Franzone 1987).
As for asthma, theophylline was also used as a bronchodila-
tor (in the same concentration range as in asthma) in the treat-
ment of chronic obstructive pulmonary disease (COPD) for
decades, but has lost popularity in this context as better toler-
ated and more effective bronchodilators have been introduced
(Barnes 2006). Chronic obstructive pulmonary disease is a
common chronic inflammatory disease of the lungs and meth-
ylxanthine positive effects on this condition have been associ-
ated with an anti-inflammatory action (Barnes 2013). This
action should be related with an effect on histone deacetylase
activity, resulting in suppression of inflammatory genes and
enhancement of the anti-inflammatory effects of glucocorti-
coids (Cosio et al. 2004; Ito et al. 2002). This mechanism may
also account for some of the anti-asthmatic effect of theophyl-
line (Ito et al. 2002).
Other than their therapeutic use against asthma, compounds
from the xanthine family have been clinically used for a long
time as first-line, safe and effective, ventilatory stimulants for
the treatment of apnea of prematurity (Abu Jawdeh et al. 2013;
Chardon et al. 2004). In fact, methylxanthines have been used
in clinical practice since the 1970’s as the major pharmacother-
apy for this condition (Aranda et al. 1977; Comer, Perry, and
Figgitt 2001; Uauy et al. 1975). Recurrent apnea is uneasily
common in preterm infants, particularly at very early gesta-
tional ages. It has been suspected to affect over 85% of neonates
born at less than 34 weeks gestation, and in virtually all neo-
nates born with less than 28 gestation weeks (Eichenwald,
Aina, and Stark 1997; Fenner et al. 1973; Hofstetter et al. 2008).
Apnea is a cessation of breathing due to immaturity of the
respiratory drive, followed by decreased oxygen saturation in
the blood and bradycardia. It may be severe enough to require
the use of positive pressure ventilation (Henderson-Smart and
De Paoli 2010). Methylxanthines have proved to be effective in
reducing the number of apneic attacks in the short term, as
well as in reducing the need for mechanical ventilation.
Caffeine and theophylline (also aminophylline) have been
the gold standard treatment for countering this condition and
reduce its consequences, but concerns about serious side effects,
such as convulsive seizures, still subsist (Bhatia 2000; El-Bitar
and Boustany 2009; Korematsu et al. 2008). Caffeine adminis-
tration (administered at 20 mg/kg doses, orally or intravenously
(Mueni, Opiyo, and English 2009)) is encouraged (with regard
to theophylline, doses of 2–6 mg/kg/day (Mueni, Opiyo, and
English 2009)) since, while displaying similar short term bene-
fits (Bhatia 2000; Henderson-Smart and De Paoli 2010), short
term side effects, such as tachycardia or feed intolerance,
appear to be mitigated by treatment with this compound (Ara-
nda et al. 2010; Bhatia 2000; Comer, Perry and Figgitt 2001;
Henderson-Smart and De Paoli 2010). Caffeine was proposed
to present a wider therapeutic window as well (A

den 2011;
Schoen et al. 2014). Apparently, also financial advantages go
along with the improved clinical outcomes, to side with caffeine
over theophylline for apnea of prematurity treatment (Aranda
et al. 2010; Schoen et al. 2014). Caffeine, improves minute ven-
tilation, CO2 sensitivity, diaphragmatic contraction, respiratory
muscle function, and neural respiratory drive, while decreasing
the hypoxic depression of breathing (Aranda et al. 2010). Caf-
feine presumably affects both the central and peripheral che-
moreceptors that control ventilation. Also, it has been reported
to significantly increase the resting hypoxic and hypercapnic
ventilatory responses in humans (D’Urzo et al. 1990; Pianosi
et al. 1994), which are controlled primarily by the peripheral
chemoreceptors located in the carotid bodies. Several studies
conducted in different animal species substantiate methylxan-
thine improvement of respiratory output (Eldridge, Millhorn,
and Kiley 1985; Hedner et al. 1985; Herlenius and Lagercrantz
1999; Kawai et al. 1995; Lagercrantz et al. 1984; Wennergren
and Wennergren 1983). Despite methylxanthine success in
stimulating neonatal breathing and the reported mechanistic
clues available, their mechanism of action as respiratory
enhancers is subject of different interpretations. While most
studies assign this therapeutic effect to an antagonism of aden-
osine receptors in central respiratory centers (Eldridge, Mill-
horn, and Kiley 1985; Hedner et al. 1985; Herlenius and
Lagercrantz 1999; Kawai et al. 1995; Lagercrantz et al. 1984;
Wennergren and Wennergren 1983), others ascribed it to inhi-
bition of cAMP-dependent phosphodiesterase-4 in the neonatal
carotid body (Mosca et al. 2014).
Finally, antitussive applications have also been anticipated
for methylxanthines, namely theobromine. Theobromine, was
reported to effectively inhibit citric acid-induced cough in con-
scious guinea pigs in vivo (Usmani et al. 2004). In fact, the
same study reported a beneficial effect in humans as well. In
this randomized double-blind study in healthy human volun-
teers, theobromine (a single oral dose of 1000 mg) proved to
increase the capsaicin (a tussive stimulant) concentration
required to induce five coughs on subjects (Usmani et al. 2004).
Theobromine seems to suppress cough by inhibiting the
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activation of afferent nerves, an effect supposedly elicited by
suppression of phosphodiesterase activity and inhibition of
bronchoconstricting adenosine A1 receptors, though other
modes of action may be involved (like the activation of Ca2C-
activated KC channels) (Smit 2011; Usmani et al. 2004). Theo-
bromine antitussive action does not induce the side effects dis-
played by other antitussive drugs. Therefore, theobromine was
even proposed as the basis for the design of a new class of anti-
tussive drugs (Usmani et al. 2004).
4.2. Cardiovascular disease
There have always been more or less generalized concerns
regarding the effects of caffeine consumption on cardiovascular
activity, and it is commonly agreed that high coffee intake may
cause tachycardia, palpitations plus a rapid rise in blood pres-
sure, and a small decrease in heart rate (Fredholm et al. 1999).
However, the fact is that it is currently accepted that moderate
caffeine intake (up to three cups of coffee) does not adversely
affect cardiovascular health (Nawrot et al. 2003; Riksen, Smits,
and Rongen 2011). Although not necessarily in a detrimental
manner, systemic administration of methylxanthines can pro-
foundly affect hemodynamic parameters, such as blood pres-
sure and heart rate (Riksen, Smits, and Rongen 2011). These
changes in cardiac hemodynamics are expected to result from
direct effects on myocardial contractility and conduction, on
vascular tone, and on the sympathoadrenal system (Riksen,
Smits, and Rongen 2011). Methylxanthines (caffeine, theobro-
mine, and theophylline) have been reported to display an active
vasodilator action on the coronary vessels, with increasing
effects ranging from caffeine to theobromine (Tarka and Cor-
nish 1982).
Caffeine administration (250 mg intravenous (Cameron,
Modell, and Hariharan 1990) or 100 mg orally (Okuno et al.
2002)) was reported to improve the microcirculation of blood
vessels in humans, while acutely increasing blood pressure
(2.2 mg/kg) (Lovallo et al. 2004; Whitsett, Manion, and Chris-
tensen 1984). Positive chronotropic and inotropic effects were
also reported for methylxanthines in humans and animal mod-
els (Cappelletti et al. 2015; Satoh 1993; Scholz 1984). The mech-
anism responsible for such effects was proposed to involve
increased cAMP levels due to inhibition of phosphodiesterase
(Riksen, Smits, and Rongen 2011). Adenosine receptor antago-
nism should not be involved in these particular actions of
methylxanthines, since the inotropic effects of theophylline and
adenosine are in fact opposite in atria, but similar in atrial and
ventricular preparations (Scholz 1984).
Methylxanthines have been pharmacologically used in
the management of cardiovascular conditions. An example
would be the use of theobromine in the context of conges-
tive heart failure and in the management of anginal syn-
drome (Batterman et al. 1959). Methylxanthines have also
been successfully employed in the treatment of bradyar-
rhythmias, in particular when involving increased extracel-
lular adenosine appearance (Cawley, Al-Jazairi, and Stone
2001; DeLago, El-Hajjar, and Kirnus 2008). These studies
illustrate the potential of the pharmacological use of meth-
ylxanthine derivatives, with higher biological activity, in the
treatment of cardiovascular diseases, which remain the lead-
ing death cause in modern societies.
Epidemiologic studies do report a degree of cardioprotection
promoted by methylxanthine consumption. Long-term moderate
consumption of coffee and tea (typically 1–3 cups per day) were
linked to reduced risk of both coronary heart disease and stroke in
healthy individuals (Bohn et al. 2012). However, the reported ben-
eficial effects may not be (at least completely) ascribed to methyl-
xanthines, since other compounds present (namely polyphenols)
also have been proposed to elicit positive outcomes (Bohn et al.
2012). Some studies specifically considered coffee consumption
only, reporting that moderate coffee consumption (1–3 cups/day
in the United States or 3–4 cups/day in Europe) may reduce the
risk of stroke and limit its consequences (Ding et al. 2014b; Lars-
son and Orsini 2011). The reduction in stroke incidence was
found for both ischemic and hemorrhagic stroke and for both
sexes (Larsson and Orsini 2011). The lowest cardiovascular disease
risk is proposed to be obtained with a coffee consumption of 3 to 5
cups per day (Ding et al. 2014b).
Another interesting recently reported action of methylxan-
thines with impact on cardiovascular health is the effect of theo-
bromine in increasing high-density lipoprotein (HDL) cholesterol.
Low serum HDL cholesterol is considered an independent and
inverse cardiovascular disease risk factor (Assmann and Gotto
2004). Cacao and cacao-derived products consumption was
shown to increase plasma HDL cholesterol and decrease plasma
low-density lipoprotein (LDL) cholesterol concentrations, contrib-
uting for cardiovascular protection and reduced risk of coronary
heart disease, as observed in several clinical trials (Baba et al. 2007;
Khan et al. 2012; Kris-Etherton et al. 1994; Mellor et al. 2010;
Mursu et al. 2004). This beneficial effect of cocoa should indeed
be assigned to theobromine and not to other possible phytochemi-
cals, like flavonoids as previously hypothesized, since it was shown
to independently and significantly increase HDL-cholesterol con-
centrations without a significant main effect of cocoa itself or an
interaction effect (Neufingerl et al. 2013). Theobromine-induced
(daily 850 mg) elevation in HDL cholesterol levels is pointed as
not being necessarily adenosine receptor-dependent (Martınez-
Pinilla, O~natibia-Astibia, and Franco 2015), and increased levels
of apolipoprotein-A-I were suggested to contribute to that effect
(Neufingerl et al. 2013). Although some of the mechanisms
involved are known, more studies are still necessary concerning
the effects of methylxanthines to the cardiovascular system. That
will open new perspectives on how these dietary-available com-
pounds may occasion useful strategies to counteract cardiovascu-
lar disorders.
4.3. Cancer
Several evidences have been gathered typifying positive out-
comes of methylxanthine consumption/administration in can-
cer contexts. Several methylxanthine-containing products have
been hinted to induce beneficial outcomes, as is the case of
cocoa extracts (in the treatment of human breast cancer (Ole-
aga et al. 2011), and coffee which is suggested to have a protec-
tive action towards colon cancer in several epidemiological
publications (Printz 2015)). Several studies also showed that tea
extracts display antimetastatic effects (Carvalho et al. 2010;
Roomi et al. 2006), and anticancer potential against renal cell
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carcinoma (Carvalho et al. 2010) and bladder cancer (Roomi
et al. 2006), although in this case chemopreventive and chemo-
therapeutic effects are still a matter of some controversy
(Conde et al. 2015). Caffeine seems to be important for the car-
cinogenic protective characteristics of tea, since decaffeinated
teas present very low (or even none) cancer inhibitory proper-
ties (Huang et al. 1997).
Through time, conflicting reports were published suggesting
mutagenic potential for caffeine (Dambrosio 1994; Lachance
1982; Rosenkranz and Ennever 1987), although today it is
assumed that the regular and normal consumption (< 300 mg
caffeine per day) would not result in mutagenic effects in
humans (Dambrosio 1994; Nawrot et al. 2003). In fact, caffeine
has been related with cancer-protective outcomes, since it was
shown to inhibit tumor proliferation (0.044% caffeine in water
for 22 weeks (Lu et al. 2006b) or 0.3% for 3 days, both in mice
(Ryzhov et al. 2007)) and vascularization (exposition of cancer
cell lines to caffeine 10 mM for 1 h) (Merighi et al. 2007). Sev-
eral types of cancer may be even positively impacted by caf-
feine, according to studies conducted in animals. That would
be the case of skin (Huang et al. 1997; Lu et al. 2002; Lu et al.
2006a), lung (Chung et al. 1998; Lu et al. 2006b) and mammary
(Yang et al. 2005) cancers. In mice (a 100 mg/kg dose) (Gude,
Menon, and Rao 2001) and posteriorly in melanoma cell lines,
(up to 5.0 mM and 3 h treatment) (Shukla and Gude 2003), caf-
feine was shown display anti-metastatic activity. Therefore, it
was suggested that it inhibits the invasion and proliferation in
melanoma pulmonary metastasis as well as in high-grade tissue
sarcoma (Shukla and Gude 2003). It has also been suggested
that, mechanistically, caffeine beneficial effects are p53 inde-
pendent (Lu et al. 2002) and may involve the promotion of cell
cycle arrest in the G0/G1 phase in cancer cells, probably
through suppression of cyclin D1-cdk4 complex activation and
consequent inhibition of retinoblastoma protein phosphoryla-
tion (Hashimoto et al. 2004).
Other than caffeine, theobromine has also been related with
positive effects in cancer. In fact, theobromine was reported to
inhibit angiogenesis in tumor growth (Barcz et al. 2000; Barcz
et al. 1998; Gil et al. 1993). In this case, theobromine action is
thought to be mediated by its interaction with adenosine A2
receptors (Barcz et al. 2000; Gil et al. 1993). Also, theobromine
has shown antitumor potential in malignant glioblastoma pro-
liferation, an effect supposed to be elicited by negative regula-
tion of phosphodiesterase 4, promoting cAMP elevation and
increasing the activity of p38 mitogen-activated protein kinase
and c-Jun N-terminal kinase, while attenuating p44/42 extra-
cellular signal-regulated kinase activity and the Akt/mamma-
lian target of rapamycin kinase and nuclear factor-kappa B
signal pathways (Sugimoto et al. 2014). The positive outcomes
elicited by theobromine in this context lead the authors to sug-
gest a rationale for a nutritional approach that could include
products containing cocoa bean extracts, with significant theo-
bromine content, for the prevention of human brain tumors
(Sugimoto et al. 2014). Finally, theophylline (20–25 mg/ml, a
range of concentrations close to that thought to be achieved
when used as anti-asthma treatment) was reported to be able to
induce cell death in carcinoma cell lines derived from human
ovarian, prostate and lung cancer (Hirsh et al. 2004). Some
studies also revealed advantages in the use of theophylline in
the context of chronic lymphocytic leukemia (Basu and Mitra
Basu 2000; Makower et al. 1999), an effect reportedly involving
promotion of apoptosis.
Other than a direct mechanistic effect on cancer, methylxan-
thines were also shown to display the ability of enhancing the
tumoricidal effect of standard antitumor drugs, such as cis-
platin, thiotepa, doxorubicin, cyclophosphamide, mitomycin C,
vincristine and methotrexate (Fingert, Chang, and Pardee 1986;
Fingert et al. 1988; Hayashi et al. 2005; Kakuyama and Sadzuka
2001; Kawahara et al. 2008; Miwa et al. 2010; Takahashi et al.
1998; Tsuchiya et al. 1992). In fact, caffeine-assisted chemo-
therapy was suggested as a viable treatment option for different
cancer manifestations (Hayashi et al. 2005; Miwa et al. 2010;
Tsuchiya et al. 1992). However, caffeine was not the only meth-
ylxanthine shown to hold positive synergistic effects with drugs
used in cancer chemo-treatment; theobromine and pentoxifyl-
line also showed promising results (Fingert, Chang, and Pardee
1986; Kakuyama and Sadzuka 2001).
The synergistic effect of methylxanthines (namely caffeine)
with antitumor drugs that induce DNA damage during cancer
management, is supposed to result from a modulating effect as
a DNA repair inhibitor (Iliakis et al. 1986). This effect would
impact postreplication repair of sublethally damaged DNA,
resulting in increased number of lethal chromosomal aberra-
tions (Byfield et al. 1981; Fingert, Chang, and Pardee 1986),
therefore enhancing cytotoxicity and antitumor activity. In
fact, caffeine was reported to directly inhibit enzymes involved
in DNA repair, as shown for DNA-dependent protein kinase
DNA-PK, which is essential for the repair of DNA double-
strand breaks (Block et al. 2004). However, it seems that most
of the effects on DNA repair impairment exerted by caffeine
and its derivatives are associated with possible arrest or abro-
gation of the cell cycle checkpoints, namely the G2/M check-
point (Bode and Dong 2007; Kawabe 2004; Sabisz and
Skladanowski 2008; Zhou et al. 2000). This checkpoint is
important for DNA repair and prevents the replication of dam-
aged DNA and the propagation of genetic abnormalities. In
fact, a large group of xanthines were assayed for G2/M check-
point inhibition assessment, with caffeine being reported as the
most effective (Jiang et al. 2000). Another possible mechanism
involved in caffeine chemotherapy enhancement would be the
induction of rapid apoptosis in spindle checkpoint-arrested
cells, in a pathway involving p21-activated kinase 1 (Gabrielli
et al. 2007). In the case of methylxanthine synergy with doxoru-
bicin in the promotion of anti-cancer action, it may not be
related to inhibitory effects on DNA repair, but rather to spe-
cific increases in doxorubicin concentration by an inhibition of
doxorubicin efflux from the tumor cells (Sadzuka, Mochizuki,
and Takino 1995).
As for chemotherapy, methylxanthines also seem to pro-
mote a sensitizing effect towards radiotherapy, as reported in
several cell lines (Busse et al. 1978; Malki, Gentry, and Evans
2006; Youn et al. 2009). The sensitization mechanism would
also involve cell cycle interference, again probably involving
G2/M checkpoint arrest, leading to jeopardized damaged-DNA
repair (Asaad et al. 2000; Jha et al. 2002; Sarkaria et al. 1999;
Wang et al. 2003; Youn et al. 2009). Methylxanthines were also
suggested to be useful if used along with tumor therapies that
are detrimentally affected by the presence of hypoxia, as is
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thought to be the case of radiotherapy (Bush et al. 1978; Dische
et al. 1983), since they were reported to generate substantial
improvements in tumor oxygenation and perfusion (Kelleher,
Thews, and Vaupel 1998). Finally, other beneficial effects eli-
cited by caffeine in the context of cancer treatments may occur
by modulation of their toxic side effects. In fact, chronic pre-
treatment with caffeine was reported to produce a significant
degree of radioprotection (Farooqi and Kesavan 1992), and
topical or intratumoral application was shown to decrease toxic
side-effects in animal models, without changes in efficacy (Heb-
bar et al. 2002). These studies reinforce the evidences that
methylxanthines do in fact display a meaningful pharmacologi-
cal potential to be used either directly used or as co-adjuvants
in cancer treatments. Nevertheless, epidemiological studies are
still needed to clarify the safety of these therapies and in vitro/
in vivo models are necessary to unveil the specific mechanisms
underlying the anticancer activity of methylxanthines.
4.4. Obesity and diabetes
Claims have been made for positive outcomes of dietary meth-
ylxanthines and methylxanthine-containing products within
the scope of obesity. For instance, regarding tea, many mecha-
nisms have been proposed to substantiate its effect counteract-
ing obesity by impacting metabolism through different
mechanisms, including lipase inhibition (Chantre and Lairon
2002), stimulation of thermogenesis (Chantre and Lairon 2002;
Dulloo et al. 1999; Dulloo et al. 2000), appetite modulation
(Liao 2001), and synergism with caffeine (Kovacs et al. 2004;
Zheng et al. 2004). But the question raised here is how much of
these effects associated with methylxanthine-containing prod-
ucts may in fact be attributed to methylxanthines themselves.
Several studies were conducted in humans addressing methyl-
xanthine effect on the management of obesity and suggested
that caffeine intake is inversely associated with body weight
increase (Lopez-Garcia et al. 2006; Westerterp-Plantenga,
Lejeune, and Kovacs 2005). Moreover, caffeine was reported to
interfere with glucose and fatty acid metabolism, reinforcing its
possible repercussions in body weight (Sugiura et al. 2012).
A lipotropic effect was proposed in the 1940’s for caffeine,
theophylline, and theobromine (Heppel, Porterfield, and Peake
1947) and another study incorporating these three methylxan-
thines showed that they generally inhibited the elevation of
body fat percentage in developmental-stage rats, suggesting a
possible role in the prevention of childhood obesity (Inoue
et al. 2006). In this study, caffeine was also shown to reduce vis-
ceral fat in the abdominal cavity, which was in line with the
results of a previous study implying an association between
long-term dietary exposure to low-dose caffeine (0.05% caffeine
in diet for 16 weeks) and decreased body fat (Zheng et al. 2004).
The effect of caffeine on body weight may be linked to an
induced decrease in the serum triglyceride level, which may
restrict the supply of fatty acid to adipose tissue and result in
body fat reduction (Inoue et al. 2006). However, the mecha-
nism that has been more consistently involved in caffeine-eli-
cited body fat decrease, involves the modulation of lipolysis
(lipid breakdown into glycerol and fatty acids). Caffeine, as well
as other methylxanthines, has been described to stimulate lipol-
ysis in vitro (Acheson et al. 2004; Bray, Mothon, and Cohen
1970; Kim et al. 2010; Kuo and De Renzo 1969). Caffeine was
proposed to prompt a decreased dependence from glycogen use
(Spriet et al. 1992), switching the substrate preference from gly-
cogen to lipids by stimulating hormone-sensitive lipase activity
(an enzyme determinant for lipolysis (Okazaki et al. 2002)) and
inhibiting glycogen phosphorylase activity (Rush and Spriet
2001). Hormone-sensitive lipase activation should derive from
inhibition of phosphodiesterase activity and the resulting
increase cAMP levels in adipocytes (Morimoto et al. 2001).
A diuretic effect has also been linked to methylxanthines for
a long time (Davis and Shock 1949). In fact, until more potent
diuretics were discovered by the middle of the last century, caf-
feine and theophylline (at doses > 250 mg) were traditionally
used to increase urine output (Osswald and Schnermann
2011). The diuretic potency of methylxanthines was established
in a number of animal and human studies to be theophylline >
caffeine > paraxanthine > theobromine (Osswald and Schner-
mann 2011). Caffeine doses eliciting significant acute diuresis
have been reported to be in the 300 mg range (about 4–5 cups
of coffee) (Grandjean et al. 2000; Maughan and Griffin 2003;
Passmore, Kondowe, and Johnston 1987; Riesenhuber et al.
2006). However, the extent of previous caffeine exposure may
decrease its diuretic effectiveness (Izzo et al. 1983) illustrating
the fact that this effect is highly dependent of dietary habits and
synergistic action of caffeine with other compounds.
Methylxanthines also promote natriuresis. In fact, methyl-
xanthine-elicited raise in urine flow may be concomitant with
increased excretion of sodium, chloride, calcium, phosphate,
magnesium and other urinary solutes (Osswald and Schner-
mann 2011).
The mechanisms taking place at the kidney level underlying
the diuretic and natriuretic effects of methylxanthines remain
unclear, but adenosine receptor antagonism and phosphodies-
terase inhibition may be involved. Pharmacological blockade of
A1 adenosine receptors was in fact reported to promote diuresis
and natriuresis, resulting in inhibition of proximal tubular
reabsorption (Knight, Bowmer, and Yates 1993; van Buren
et al. 1993; Wilcox et al. 1999), and A1 receptors have been
reported to be necessary for caffeine and theophylline-induced
inhibition of renal reabsorption (Rieg et al. 2005). On the other
hand, phosphodiesterase inhibition in the proximal tubule has
also been suggested to contribute to the diuretic and natriuretic
effects of methylxanthines (Coulson and Scheinman 1989;
Fredholm, Hedqvist, and Vernet 1978).
Another field of research that has been disclosed for methyl-
xanthines, concerns their putative usefulness within the sphere
of diabetes. Diabetes mellitus is one of the greatest health
threats arising from the modern global dietary options and
daily habits. It is classified as type 1 or 2, with type 1 involving
complete lack of insulin-production, while type 2 is character-
ized by impaired insulin secretion and increased insulin resis-
tance (Association 2010). Epidemiological and prospective
studies have in fact insinuated a connection between coffee
consumption and a decreased risk of developing type 2 diabetes
mellitus (Bhupathiraju et al. 2013; Bidel et al. 2006; Biessels
2010; Muley, Muley, and Shah 2012; Paynter et al. 2006; Sartor-
elli et al. 2010; van Dam and Feskens 2002; van Dam and Hu
2005). A recent meta-analysis proposed that the relationship
between coffee consumption and the risk of developing type 2
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 2605
diabetes mellitus occurs in an inverse dose–responsive manner,
with protection increasing progressively from no or rare coffee
consumption to 6 cups/day, in 1-cup-a-day increments (Ding
et al. 2014a). However, caffeine direct involvement in the pro-
moted protection towards the disease induced by coffee is a
matter of controversy. It seems that caffeine may not be the
only responsible for the effects produced by coffee, since both
caffeinated and decaffeinated coffee were associated with
reduced diabetes risk (Ding et al. 2014a; Pereira, Parker, and
Folsom 2006; van Dam et al. 2006). Moreover, caffeine was
reported to decrease glucose uptake (with a 5 mg/kg single oral
dose) (Greer et al. 2001) and also increase insulin insensitivity
(with a 3 mg/kg single intravenous dose, and posterior continu-
ous infusion to maintain blood concentration) (Keijzers et al.
2002) in humans. Therefore, attention should be payed to other
phytochemicals present in coffee, like phenolic compounds, as
prospective improvement agents within the context of diabetes
other than caffeine.
Coffee is not the only methylxanthine-containing beverage
for which beneficial effects towards type 2 diabetes mellitus
incidence have been reported. Tea consumption has also been
associated with a lower risk of developing the disease (Dieren
et al. 2009; Yang et al. 2014). Studies in animals have pointed
positive effects for tea consumption on prediabetic rats, report-
ing improved metabolic status and prevention of most of the
heart-related deleterious effects evaluated (Alves et al. 2015).
Moreover, tea protective effects also took place in the cerebral
cortex and oxidative profile of the prediabetic rat model, after
two months of tea consumption (Nunes et al. 2015). Tea also
proved to decrease glucose intolerance and increase insulin sen-
sitivity in the same animal models (Alves et al. 2015) and was
therefore suggested as an alternative co-adjuvant in the treat-
ment or prevention of diabetes pathophysiology (Nunes et al.
2015).
Consistent proof of methylxanthine direct involvement in
diabetes prevention is scarce and more targeted studies should
be envisioned to address their putative effects. However, since
both pancreatic cell insulin secretion (Seino et al. 2009) and
liver glucose output (Vilela et al. 2014) are dependent on the
intracellular concentration of cAMP, and since methylxan-
thines modulate phosphodiesterase activity (even though only
at considerable concentrations, as we have discussed before), it
has been speculated that these compounds may positively
impact the glucose metabolism in humans (Sarria et al. 2015).
Theobromine may also be an interesting subject to investigate
in this scope, since it was reported to reduce extracellular
matrix accumulation and oxidative stress in the kidneys of dia-
betic rats (Papadimitriou et al. 2015). In fact, the authors of
this study suggested Sirt-1 activation by theobromine to have
therapeutic potential in the context of diabetic nephropathy.
4.5. Neurological and neurodegenerative disease
Taking into account that methylxanthines have the ability to
cross the blood-brain barrier (Somani, Khanna, and Bada
1980) and that the adenosinergic system is omnipresent in the
CNS (Trincavelli, Daniele, and Martini 2010), these com-
pounds are expected to have a marked overall impact on neuro-
nal function. In fact, the impact of methylxanthines in the
nervous system is largely substantiated. Analgesic drugs exert
their effects in various ways on the peripheral and central ner-
vous systems. The use of methylxanthines, namely caffeine as
an analgesic, especially as an analgesic adjuvant has been
reported to maximize pain relief when combined with other
common analgesics (paracetamol, ibuprofen or aspirin) (Derry,
Derry, and Moore 2014; Laska et al. 1984). Methylxanthine
(caffeine, pentoxifylline, and theophylline) anti-inflammatory
action has been explained as the result from two main mecha-
nisms: non-selective phosphodiesterase inhibition and as a
non-selective adenosine receptor antagonism (Lee et al. 2014).
Another interesting effect of methylxanthines is the reported
improvement of locomotive function. In the 1980’s methylxan-
thines (caffeine and theophylline) were proposed to enhance
locomotor activity in mice (Seale et al. 1986). Adenosine recep-
tor antagonism was proposed as the main mechanism of action
responsible for these locomotor activating effects of methylxan-
thines (Snyder et al. 1981). More recently paraxanthine was
found to have a significantly stronger impact in locomotor acti-
vation than caffeine, theophylline and theobromine in rats.
This study proposed, however, phosphodiesterase inhibition
(most likely PDE9 inhibition) as the main mechanism respon-
sible for such effects (Orru et al. 2013). Other studies reinforce
the beneficial effects of caffeine intake in improving motor
activity in the context of neurodegenerative diseases, although
trough mechanisms of neuroprotection and neurorestoration
by trophic proteins (Airavaara et al. 2012; Chen and Chern
2011; Rosim et al. 2011).
Other beneficial effects traditionally reported for caffeine in
the context of the nervous system include prophylactic effects
on post-lumbar puncture headache (Nguyen and Walters 2014;
Ragab and Facharzt 2014), and reduced neuronal damage after
ischemic insult (in this case, with long-term administration of
caffeine) (Rudolphi et al. 1989), as well as neuroprotective
effects against spinal cord injury (SCI) (Rivera-Oliver and
Dıaz-Rıos 2014a). As for theophylline, it was reported to effec-
tively suppress the occurrence of spike–wave discharges (fol-
lowed by recording electroencephalograms) in a genetic model
of absence epilepsy (WAG/Rij strain rats). The greatest sup-
pression of spike–wave discharges in this model was achieved
with 20 mg/kg theophylline (Ates, Sahin, and Ilbay 2004).
Probably the most commonly acknowledged effect of caf-
feine, and the reason why many people ingest it through cof-
fee, is its psychostimulatory activity. Caffeine does produce a
dose-dependent generalized psychostimulation trough CNS
activation, resulting in sensations of increased alertness and
ability to maintain an intellectual effort, along with decreased
tiredness and fatigue, even in situations of sleep deprivation
(Beaumont et al. 2005; Lozano et al. 2007). A similar psychos-
timulant effect was reported for chocolate, resulting from the
combination of caffeine and theobromine in the proportions
found in cacao (19 and 250 mg, respectively, representing a
50 g bar of dark chocolate) (Smit, Gaffan, and Rogers 2004). It
was proposed that caffeine would exert its effects on alertness
through CNS-mediated actions, while theobromine would be
acting primarily via peripheral physiological changes (Mitch-
ell et al. 2011).
Other than the aforementioned psychostimulant activity,
cognitive benefits in humans have also been consistently
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associated with caffeine alone (40–500 mg) (Lieberman 2001)
or in combination with L-theanine, mimicking tea consump-
tion (Giesbrecht et al. 2010). In animal models, evidence was
gathered supporting a cognition-enhancing role for caffeine
(0.3–10 mg/kg ip) in a variety of behavioral tasks that evaluated
learning and memory (Angelucci et al. 2002; Takahashi, Pam-
plona, and Prediger 2008). Apparently, these effects do trans-
late to humans (Haskell et al. 2005), and brief exposure to
caffeine (a single-take of 250 mg in coffee) proved to improve
memory and cognitive function in the scopolamine-induced
amnesia model (Riedel et al. 1995). Moreover, caffeine was also
reported to improve attention and information processing
(Lorist and Tops 2003). In fact, caffeine has been suggested as a
pertinent candidate for counteracting memory loss (Cunha
2008) and a significant number of prospective studies pointed
protective effects against cognitive decline elicited by frequent
coffee or caffeine consumption (Arab et al. 2011; Ritchie et al.
2010; Ritchie et al. 2007; Santos et al. 2010; van Gelder et al.
2006; Vercambre et al. 2013), although there are reports that
do not validate such association (Laitala et al. 2009; van Boxtel
et al. 2003). Other recent prospective data reported high plasma
caffeine levels as being associated with reduced risk of demen-
tia, particularly for those who already have mild cognitive
impairment (MCI) (Cao et al. 2012). However, epidemiological
studies in humans have yet failed to establish a causal relation-
ship between caffeine/coffee consumption and a lower risk of
dementia (Carman et al. 2014).
One of the main sources of the interest that currently sur-
rounds methylxanthines, are their reported neuroprotective
potential (Cunha 2005; Duarte et al. 2009; Guerreiro et al.
2008; Ritchie et al. 2007). A fair amount of scientific research
has been conducted within this scope pointing plausible mech-
anisms of neuroprotection while some epidemiological studies
suggest some promise. These neuroprotective effects have been
better disclosed within the context of neurodegenerative dis-
ease. Sporadic Alzheimer’s and Parkinson’s diseases are the
most common conditions accounting for the present worri-
some neurodegenerative epidemic, but they still conceal
unknown etiologies and are currently addressed with limited
therapeutic resources. In fact, caffeine consumption has been
related with a reduction in the incidence of two of the most
prevalent neurodegenerative diseases, and evidences of such
beneficial effects have been gathered from both animal and
human studies (Alzheimer’s (Arendash and Cao 2010; Eskeli-
nen et al. 2009; Maia and de Mendonça 2002) and Parkinson’s
(Chen et al. 2001; Costa et al. 2010; Joghataie et al. 2004; Post-
uma et al. 2012)). In such complex neurological conditions as
these, antagonism of the adenosine receptors, namely A1 and/
or A2A receptor subtypes, was suggested to offer therapeutic
benefits and to be the primary target of the neuroprotective
effects of caffeine (Dore et al. 2011; Van der Walt and Terre’-
Blanche 2015). Another common mechanism for the beneficial
effects of caffeine both in Alzheimer’s and Parkinson’s disease
would be protection against blood-brain barrier dysfunction.
This event has been implicated in the pathogenesis of Alz-
heimer’s (Kalaria 1992; Kalaria 1999) and in Parkinson’s as
well, although more controversially (Kortekaas et al. 2005; Stolp
and Dziegielewska 2009). However, chronic ingestion of
caffeine was reported to hold a protective effect against blood-
brain barrier dysfunction both in a rabbit model of sporadic
Alzheimer’s disease (3 mg in drinking water for 12 weeks)
(Chen et al. 2008a) and also in a mouse model of Parkinson’s
disease (10 mg/kg, ip, for two weeks) (Chen et al. 2008b).
A considerable amount of studies conducted in vitro and in
animal models and in animal models of neurodegenerative dis-
orders have provided compelling physiologic support for caf-
feine’s neuroprotective effects within the scope of these
diseases.
In the case of Alzheimer’s disease, the neuroprotective
potential of caffeine has been demonstrated in mouse models.
Both acute or long-term caffeine administration were shown to
reduce brain amyloid-b- peptide (Ab) production and accumu-
lation in transgenic mice models of Alzheimer’s disease and in
cultured neurons taken from these animals (Arendash et al.
2009; Arendash et al. 2006; Cao et al. 2009; Chu et al. 2012), as
well as in a rabbit model of the pathology (Prasanthi et al.
2010). Caffeine has also been reported to improve cognitive
performance in animal models of Alzheimer’s disease (Are-
ndash et al. 2009; Arendash et al. 2006; Chu et al. 2012), and to
restore memory and reverse the pathology in mice with pre-
existing Ab burden (Arendash et al. 2009).
The long-term neuroprotective effect of caffeine was pro-
posed to take place by competitive antagonism of excessive acti-
vation of adenosine A2A receptors in the hippocampus and
cortex, which may attenuate the synaptoneurotoxicity induced
by Ab (Dall’Igna et al. 2007; Dall’lgna et al. 2003; Prediger,
Batista, and Takahashi 2005). However, A1 receptors may also
play a role in caffeine-mediated neuroprotective effects. In fact,
Alzheimer’s disease patients showed a reduced density of aden-
osine A1 receptors (Kalaria et al. 1990; U»as et al. 1993) and the
blockade of these receptors has been reported to promote cog-
nitive benefits in rodents (Maemoto et al. 2004). Moreover,
selective adenosine A1 receptor antagonists were proposed as
potential targets for the treatment of cognitive impairments,
such as those occurring in patients with Alzheimer’s and Par-
kinson’s disease (Mioranzza et al. 2011; Pereira et al. 2002;
Ribeiro and Sebasti~ao 2010). Other complementary mecha-
nisms that have been proposed to account for caffeine benefi-
cial action in animal models of the disease are the ability of
caffeine to decrease hippocampal levels of pro-inflammatory
cytokines (a daily oral dose of  1.5 mg caffeine/mouse for
2 months) (Cao et al. 2009) increased caffeine-induced release
of intracellular calcium in neurons (25 mM in cortical cultures)
(Smith et al. 2005), enhanced brain mitochondrial function
(0.3 mg in drinking water for two months, in mice) (Dragicevic
et al. 2012) and increased cerebrospinal fluid production (0.6 g/
L caffeine in water for 3 weeks, in rats) (Han et al. 2009; Wos-
tyn et al. 2011).
The discussed findings are somehow supported by epidemi-
ologic results. In fact, the main conclusion elicited from epide-
miology is the establishment of a link between chronic caffeine/
coffee consumption during the middle stages of life and a sig-
nificantly lower risk of developing neurodegenerative diseases,
namely Alzheimer’s disease (Eskelinen et al. 2009). Both pro-
spective (Eskelinen et al. 2009; Johnson-Kozlow et al. 2002;
Lindsay et al. 2002; Ritchie et al. 2007; van Gelder et al. 2006)
and retrospective (Maia and de Mendonça 2002) studies have
investigated the impact of long-term consumption of caffeine
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 2607
with regard to this pathology, linking chronic caffeine intake
with lower risk for the incidence and mitigation of disease pro-
gression. In these studies, lifetime coffee intake is considered
and regular consumption of coffee was defined as nearly every-
day. Maximal protective action is described by several studies
as being achieved by the consumption of 3 coffee cups per day.
Despite all the evidence compiled from basic science and epide-
miological studies, the etiology of Alzheimer disease remains
unrevealed, and an unequivocal basis for caffeine-driven bene-
ficial effects can only be speculated. Therefore, the promise of a
putative caffeine-based therapy for Alzheimers disease remains
adjourned.
Similarly to Alzheimer’s disease, caffeine has been linked to
beneficial effects in the progression of Parkinson’s disease,
although the mechanisms involved in the process are also far
from being clarified (Rivera-Oliver and Dıaz-Rıos 2014b). Aden-
osine receptor blockade was first proposed in the 1970s as the
mechanism for the protective activity of caffeine in the context of
this disease (Fuxe and Ungerstedt 1974). However, the molecular
mechanisms by which inhibition of adenosine receptors protects
dopaminergic neurons from degenerating remains elusive. Both
epidemiologic and experimental evidence converge, suggesting
that caffeine and selective adenosine A2A receptor antagonists
represent interesting strategies to attenuate dopaminergic neuro-
degeneration in Parkinson’s disease. In fact, studies performed in
rat models revealed that caffeine administration prevented the
loss of nigral dopaminergic neurons, indicating a role for caffeine
in delaying neuronal degeneration (Chen et al. 2001; Li et al.
2008; Sonsalla et al. 2012). Moreover, chronic antagonism of
adenosine A2A receptors was shown to improve themotor deficits
elicited by Parkinson’s disease (Morelli, Carta, and Jenner 2009).
The other well established molecular target for the treatment of
Parkinson’s disease is monoamine oxidase (MAO), particularly
the MAO-B isoform (Petzer and Petzer 2015). Caffeine and,
more efficiently, other caffeine-derived compounds have been
shown to inhibit this enzyme (Petzer, Pienaar, and Petzer 2013),
making the quest for effective dual-target-directed compounds,
which would act at both major therapeutic targets hinted for Par-
kinson’s disease, very appealing. Stabilization of the blood-brain
barrier may be another mechanism by which caffeine counters
Parkinson’s disease (Chen et al. 2008b). Finally, anti-neuroin-
flammatory action combined with a reduction of neuron oxida-
tive damage was also recently suggested as a plausible protection
mechanism prompted by caffeine (Go»embiowska et al. 2013).
Several epidemiologic studies have also suggested an inverse,
dose–response relationship between coffee/caffeine consump-
tion and the risk of Parkinson’s disease incidence (Ascherio
et al. 2001; Benedetti et al. 2000; Costa et al. 2010; Palacios
et al. 2012; Qi and Li 2014; Ross et al. 2000a; Saaksjarvi et al.
2007). Regarding the studies addressing coffee consumption,
caffeine was suggested as being the causal factor of the
prompted favorable effects (Palacios et al. 2012). This beneficial
effect is also linked to consumption at midlife (in this case 2 or
more cups of coffee per day). A very recent dose-response
meta-analysis encourages the ingestion of 3 cups of coffee a
day, since it may be the optimal protective dose of caffeine for
Parkinson’s disease prevention (Qi and Li 2014).
As for Alzheimer’s disease, the proper mechanism of caf-
feine-induced protection is not fully clarified yet. Other than
the beneficial clues listed before within the scope of Alzheimer’s
and Parkinson’s disease, also Machado-Joseph disease appears
to be favourably impacted by caffeine (Gonçalves et al. 2013).
On the other hand, a retrospective study has recently linked
caffeine to detrimental effects in Huntington’s disease (Simonin
et al. 2013), suggesting that the underlying mechanisms of its
interference within the scope neurodegenerative diseases
encompasses an intrinsic complexity that should indeed be fur-
ther studied.
4.6. Human fertility
The impact of methylxanthines on human fertility as also been
the focus of several studies. Interestingly, results greatly differ
between sexes and remain under intense debate. A study
showed that high maternal consumption of caffeine (more than
3150 mg/month, or about one cup of brewed coffee a day)
could be related to reduced fertility in women trying to get
pregnant (Wilcox, Weinberg, and Baird 1988). On the other
hand, regarding male reproductive system, it is suggested that
moderate consumption of caffeine should be safe (50 mM in
cell lines, corresponding to a plasma concentration of 10 mg/
mL (Dias et al. 2015)). Moreover, the nutritional support of
spermatogenesis by Sertoli cells appeared to be enhanced after
exposure to caffeine (50 mM), and this should result in a gen-
eral improvement of male fertility (Dias et al. 2015).
Male infertility is unfortunately relatively common, account-
ing for about 50% of the problems affecting couples with fertility
problems (Dohle et al. 2005). Usually, in situations of male sub-
fertility or infertility, the condition is due to loss of sperm func-
tion rather than decreased number of spermatozoa (Hull et al.
1985) and thus sperm quality is a valuable marker for male
reproductive health. Methylxanthines have been studied within
the scope of sperm function, and unlike the aforementioned epi-
demiologic hints regarding female fertility, positive effects have
been unveiled. A positive effect of methylxanthines (0.15–
1.2 mM) on abalone sperm Ca2C transport was reported, and
the suggestion was made that their activity on sperm function
could be mediated through changes in Ca2C conductance (Kopf,
Lewis, and Vacquier 1984). The activity of methylxanthines as
phosphodiesterase inhibitors was also involved in the beneficial
effects of methylxanthines, through regulation of cAMP levels.
In fact, cAMP levels are positively correlated with increased
motility (Tash and Means 1982) and there is evidence that
cAMP-dependent phosphorylation is involved in the activation
of spermatozoa motility when they are released from storage in
the male reproductive tract (Brokaw 1987). Both mechanisms
may in fact be decisive for fertilization, since increase in intracel-
lular calcium and cAMP are reported to be important in several
steps of the process (Yoshida, Kawano, and Yoshida 2008).
Among the common dietary products that contain methylxan-
thines, tea was the one recently proposed to elicit positive out-
comes in male fertility. A tea extract (white tea), was reported to
alter the glycolytic profile of cultured Sertoli cells, stimulating lac-
tate production. Besides its importance as a metabolic substrate, a
role as an anti-apoptotic agent in the developing germ cells was
also proposed for lactate and, therefore, white tea consumption
was suggested as being advantageous to male reproductive health
(Martins et al. 2013). Notably, animal studies provided compelling
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evidence that white tea consumption can counteract the deleteri-
ous effects of prediabetes on male reproductive health by improv-
ing sperm concentration and quality after two months of
exposure to the drink (Oliveira et al. 2015). Interestingly, white tea
was also suggested as a promising media additive for sperm stor-
age at room temperature, helping to avoid the deleterious effects
brought by refrigeration (Dias et al. 2014). These studies provide
compelling evidence of the pharmacological potential of white tea,
known to be rather methylxanthine-rich, in the context of male
reproductive health.
Although many beneficial effects have been proposed for sev-
eral tea components, namely catechins and L-theanine (Cooper
2012; Huber 2003; Matsui 2015), at least some of the beneficial
effects proposed within the scope of male fertility may be specifi-
cally assigned to the caffeine content. Caffeine was shown to
modulate Sertoli cell metabolism and promote, by itself, stimula-
tion of lactate production at concentrations mimicking moderate
dietary consumption (Dias et al. 2015). Moreover, caffeine
(1.15 mM, in Beltsville thawing solution supplemented with
CaCl2) was also suggested as an effective additive in the context
in vitro fertilization, since it was reported to improve the proba-
bility of pregnancy in gilts and sows by boar semen (Yamaguchi,
Funahashi, and Murakami 2009). Nevertheless, more work will
be needed within this scope in order to unveil the full potential
of methylxanthines in the context of sperm conservation and,
more broadly, in male fertility.
5. Detrimental effects
Taking into account that natural methylxanthines are thought
to be biosynthesized by plants as a protection mechanism
against insect feeding, and are biopesticidal at concentrations
known to occur in plants (Nathanson 1984), concerns raised
about putative toxicity are justified.
The toxicity of methylxanthines may greatly vary, depending
on the specific compound and the animal in question (Table 3).
In rats LD50’s are 200 mg/kg for caffeine, 206 mg/kg for the-
ophylline and 950 mg/kg for theobromine (Tarka and Cornish
1982). In humans, the values are relatively close to those in rats
with LD50’s of 192 mg/kg for caffeine, and 1000 mg/kg for theo-
bromine. Thus, human acute toxicity towards methylxanthines
is very low. For instance, for caffeine the acute toxic level
should be about 10 g/day, which would be comparable to
drinking 100 cups of instant coffee (Cappelletti et al. 2015). It is
important to notice that, in fact, individuals vary in their sensi-
tivity to methylxanthines, and some of those fluctuations may
be genetically originated (Alsene et al. 2003; Hart, de Wit, and
Palmer 2012; Rogers et al. 2010).
Nevertheless, methylxanthine acute toxicity in humans is
rather low. Although a great inter-species variability may occur
the values for humans (LD50’s of 192 mg/kg for caffeine and
1000 mg/kg for theobromine) are very close to the ones
reported for rats (Tarka and Cornish 1982) (Table 3). There is
overwhelming scientific evidence proving that moderate con-
sumption of caffeine from common sources is safe (2014; Glade
2010). Coffee/caffeine consumption should not be harmful up
to doses of 200 mg in one sitting (about 21/2 cups) or 400 mg
daily (about 5 cups) (Nehlig 2015). Therefore, daily caffeine
ingestion was suggested to be harmless in terms of general tox-
icity, or in terms of detrimental consequences to cardiovascular
function, bone status and calcium balance, cancer incidence
and negative changes in adult behavior (Nawrot et al. 2003).
However, deleterious effects may emerge from consumption of
diet supplements enriched in caffeine (Pendleton et al. 2012;
Pendleton et al. 2013) or if caffeine is combined with drugs of
abuse (Sinchai et al. 2011). Thus, attention should be paid to
the rapidly expanding energy drink market, since these bever-
ages contain amounts ranging from 50 mg to alarming 500 mg
per can or bottle (Cappelletti et al. 2015).
Acute toxicity due to excessive caffeine intake is not very com-
mon. When it occurs, it may elicit several intoxication manifesta-
tions, such as elevated respiration, gastrointestinal disturbances,
insomnia, nervousness, headache, tachycardia, arrhythmia, nau-
sea, seizures, and even death (Clauson et al. 2008; Nawrot et al.
2003). Reports describing death provoked by excessive intake of
caffeine are scarce (Nawrot et al. 2003). The average post-mortem
concentration of caffeine reported in fatal caffeine intoxication
was 140 mg/L (Banerjee et al. 2014). Chronic effects raised by
excessive caffeine consumption, may be expressed by dysfunctions
involving the gastrointestinal and renal systems, liver and muscu-
lature (Nawrot et al. 2003; Stavric 1988b). Several sporadic studies
have implied caffeine/coffee consumption in other detrimental
actions. For instance, epidemiologic studies made an association
between elevated coffee intake and increase risk of ischemic
stroke (Mostofsky et al. 2010), what somehow contradicts some
of the beneficial effects on vascular function discussed above.
An issue that has been raising controversy for some time is
whether or not caffeine should be classified as a drug of abuse.
Some say yes, since it creates dependence, highlighting its actions
regarding positive reinforcement, tolerance promotion, and the
existence of withdrawal syndrome after stopping its consumption
(Lozano et al. 2007). Others disagree, saying that the relative risk
of physical dependence to caffeine is quite low (Nehlig 1999) and
that withdrawal is brief and relatively mild (Nawrot et al. 2003).
Moreover, many studies claim that moderate coffee drinkers do
not develop a physical dependence to caffeine at all (Nehlig 2015).
A compelling vindication against the case of caffeine being a drug
of abuse is brought by the realization that caffeine does not stimu-
late dopaminergic transmission in the shell of the nucleus accum-
bens (which is thought to be a specific feature of drugs of
dependence (Nehlig 2004)) and that human imaging studies
showed that it does not activate the brain circuit of dependence
and reward (Nehlig, Armspach, and Namer 2010b).
Caffeine has also raised concerns in a sports context. Studies
emerged pointing caffeine as a performance enhancer, namely
in activities relying on explosive strength (Jacobson et al. 1992),
short-term, high-intensity exercise (Anselme et al. 1992; Jack-
man et al. 1996), and activities depending on aerobic activity
and endurance (Graham and Spriet 1991; Greer, Friars, and




Man 150–200 1000 (no data available)
Rat 200 950 206
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Graham 2000; Kovacs, Stegen, and Brouns 1998). Caffeine use
was regulated by the competent institutions, namely the Inter-
national Olympic Committee, and a concentration of 12 mg/
mL in urine was defined as the accepted upper limit (Chapman
and Mickleborough 2009).
As for theophylline, it showed promise as CNS stimulant,
although it is mainly used in respiratory disease therapy
(namely chronic obstructive pulmonary disease and asthma
(Barnes 2013)). It has also been proposed as having applica-
tions as a diuretic (Bell et al. 1998). Theobromine has showed
significant less CNS activity than caffeine and theophylline,
possibly because of physicochemical properties that hinder its
distribution in the CNS (Salihovic et al. 2014).
In both rodents and humans, theobromine seems to be
safer than caffeine, since oral lethal doses are even higher
(Franco, O~natibia-Astibia, and Martınez-Pinilla 2013). Theo-
bromine also seems devoid of carcinogenic effects (Rosenkranz
and Ennever 1987). However, theobromine, is significantly
toxic in other mammals, including pets (namely dogs) (Eteng
et al. 1997; Smit 2011). The reasons that underlie this differen-
tial toxicity are not well established, but this should be a
trademark example of a compound whose mechanisms of
action significantly vary between humans and other mammals
(Martınez-Pinilla, O~natibia-Astibia, and Franco 2015). These
toxic effects of theobromine in susceptible species may be
enhanced since it displays a relatively higher half-life than caf-
feine (Baggott et al. 2013), increasing systemic exposure. The
awareness of adverse effects in some animals, prompted clini-
cal trials, generally subscribing the harmlessness of theobro-
mine for humans in regular intake ranges (Baggott et al.
2013). Given its limited toxicity in humans, theobromine
chronic effects and studies targeting them are very scarce.
Nevertheless, one such study reported some side-effects
(namely involved sweating, trembling and severe headaches)
to be linked to long-term consumption of large quantities of
cocoa products (the daily equivalent of l.5 g methylxanthines)
(Czok 1974).
Although some similarity exists between theophylline and
caffeine in terms of pharmacological and toxicological proper-
ties, the first has been suggested to display stronger toxic effects
(Stavric 1988b). That was the reason for caffeine to be preferred
over theophylline in the treatment of respiratory conditions
(Henderson-Smart and De Paoli 2010; Schoen et al. 2014). The
more pronounced toxic effects of theophylline may be related
with its extended half-life, which is about twice that of caffeine
(Gilbert 2004). Unwanted effects of theophylline are related to
plasma concentration, and tend to manifest when plasma con-
centration exceeds 20 mg/L (Barnes 2013). Frequent side-
effects of theophylline administration may include headache,
nausea (vomiting even), increased acid secretion and gastro-
esophageal reflux (Barnes 2013). At higher concentrations, the-
ophylline may cause convulsions and cardiac arrhythmias
(Barnes 2013; Stavric 1988a).
Chronic effects of theophylline should only occur insidi-
ously in patients receiving the drug therapeutically (Sessler
1990; Tsai et al. 1994) and should almost always occurs as
a result of chronic oral administration (Minton and Henry
1996). Chronic toxicity may result of doses that are too
high or of particular factors which somehow jeopardize its
clearance, as may be the case of concurrent medication
changes or disease states (Minton and Henry 1996). The
features of theophylline chronic exposure should be similar
to those of acute toxicity. However, the differences noted
should include increased susceptibility to the drug (Shannon
1993), and more frequent seizures and serious arrhythmias
in patients who suffered chronic overdosing, induced at
lower serum concentrations with regard to those given an
acute single overdose (Olson et al. 1985). These reports led
to clinical suggestions for patients with chronic theophylline
poisoning to receive extracorporeal aid in drug removal
(hemoperfusion or hemodialysis) (Heath and Knudsen
1987; Olson et al. 1985; Shannon and Lovejoy 1992).
Paraxanthine is the major metabolite of caffeine in
humans, and its plasma levels are normally two thirds those
of caffeine (Benowitz et al. 1995). Paraxanthine is thought
to be a rather innocuous compound for humans (Stavric
1988c). Another caffeine metabolite, 1-methylxanthine, was
shown to inhibit the transport activity of human organic
anion transporter 1 in vitro (Rengelshausen et al. 2004), in
a more potent manner than caffeine and other xanthine
derivatives (Sugawara et al. 2005). This transporter is
implied in the renal excretion of numerous drugs. This
interference may alter the pharmacokinetics of clinically
important drugs in humans (Babu et al. 2002; Takeda et al.
2002a; Takeda et al. 2002b). Therefore, caffeine, through its
metabolite 1-methylxanthine, may modulate the toxic effects
of other compounds, and this may also help explain the
potentiating action of caffeine on the effects of other drugs.
Also, there is considerable evidence that should not be disre-
garded regarding possible detrimental actions of methylxan-
thines on male reproductive system, and that should be
weighed against the positive effects discussed in the previous
section. Methylxanthines (namely caffeine, theophylline and
theobromine) were reported to promote testicular atrophy and
aspermatogenesis (Friedman et al. 1979; Gans 1984; Wein-
berger et al. 1978). Theobromine was consistently reported to
have detrimental effects on animal male reproductive system in
a number of studies (Soffietti et al. 1989; Tarka, Zoumas, and
Gans 1979). However, the concentrations of methylxanthine
that lead to some of these effects are significantly high, and
would be difficult to attain by human consumption (Tarka and
Cornish 1982).
Despite the fact that the use of methylxanthine is com-
monly considered fairly safe on the doses achievable by
normal consumption, the most common concern is still
related with prenatal exposure. Methylxanthines may cross
the placental barrier in humans, enabling fetus exposure
(Skopinski et al. 2011), an event that may result in hazard-
ous outcomes since the developing fetus may not possess
the fully developed detoxification enzymes (Eteng et al.
1997). This is a field that has been somewhat overlooked
and deserves special attention in the future.
Several studies have been conducted focusing on methyl-
xanthine prenatal exposure and possible detrimental effects.
Epidemiologic studies go either way in terms of reporting
methylxanthine detrimental impact on pregnancy. An early
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study showed that caffeine intake did not hold consequen-
ces on pregnancy outcome and general offspring develop-
ment (Barr and Streissguth 1991). Other studies reported
no effects for moderate coffee consumption on neonatal
birth weight or the length of human gestation (Bech et al.
2007), on the incidence of cardiovascular malformation
(Browne et al. 2007; Jahanfar and Jaafar 2013, 2015), or on
the risk of birth defects (Browne et al. 2011). Others report
that caffeine intake slightly increases the risk of fetal growth
restriction (Group 2008), the risk of miscarriage (Weng,
Odouli, and Li 2008), the risk of delivering a baby with
spina bifida, anencephaly or encephalocele (Schmidt et al.
2009), increases “small for gestational age” (SGA) births
(Hoyt et al. 2013), increases the incidence of congenital
limb deficiencies (Chen et al. 2012), and increases the risk
of delivering a male infant with neonatal cryptorchidism (in
this case, only for intakes exceeding 400 mg/day) (Mon-
graw-Chaffin et al. 2008). Taking all these studies into
account, and despite inconsistencies in the results, it may
seem sensible to encourage pregnant women to limit coffee
consumption, even more in the case of reproductive-aged
women, who were proposed as a susceptible risk group
(Kuczkowski 2009).
Evidences of putative detrimental methylxanthine actions
during pregnancy were also gathered from animal studies.
Caffeine in moderate doses was shown to affect normal sex-
ual differentiation of the fetal testes in rats (Pollard, Wil-
liamson, and Magre 1990). Another study reported that
theobromine affected progeny development in both prenatal
and postnatal periods. In that study, a theobromine-
enriched diet significantly inhibited embryo growth and tis-
sue proangiogenic activity in mice, and reduced neonatal
relative limb size (Chorostowska-Wynimko et al. 2004).
Skopinski and colleagues (Skopinski et al. 2011) finely
reviewed the existing literature regarding prenatal exposure
to methylxanthines in animals and concluded that prenatal
exposure can produce changes in the developing organism
that may persist in further stages of life. However, they also
concede that inferences made upon the available data may
Table 4. Reported methylxanthine medical use.
Condition Methylxanthine Doses Proposed Mechanism
Respiratory Asthma (Barnes 2013) Theophylline 10–20 mg/L (55–
110 mM)
phosphodiesterase inhibition (Barnes 2005; Barnes 2013)
antagonism of adenosine receptors (Fozard and McCarthy 2002;
Russo, Arcidiacono, and Polosa 2006)
Chronic obstructive pulmonary disease
(Barnes 2006)
Theophylline 10–20 mg/L phosphodiesterase inhibition (Barnes 2006)
Apnea of prematurity (Scanlon et al. 1992) Caffeine 13–20 mg/L antagonism of adenosine receptors (Eldridge et al. 1985; Hedner et al.
1985; Herlenius and Lagercrantz 1999; Kawai et al. 1995;
Lagercrantz et al. 1984; Wennergren and Wennergren 1983)
Theophylline 13–20 mg/L phosphodiesterase inhibition (Mosca et al. 2014)
Cough (Usmani et al. 2004) Theobromine 32 mg/kg phosphodiesterase inhibition and/or antagonism of adenosine
receptors (Smit 2011; Usmani et al. 2004)
Cardiovascular Congestive heart failure and anginal
syndrome (Batterman et al. 1955)
Theobromine single dose of
200 mg
(not suggested)
Bradyarrhythmias (Benditt et al. 1983;
Cawley et al. 2001)
Theophylline 9–12 mg/L antagonism of adenosine receptors (Evoniuk, von Borstel, and
Wurtman 1987)
HDL cholesterol increase (Neufingerl et al.
2013)




Cancer Chronic lymphocytic leucemia (Makower
et al. 1999)
Theophylline 300 mg twice daily
for at least a
month
phosphodiesterase inhibition, modulation of protein expression
(Makower et al. 1999)
Cancer treatment enhancement (Hayashi
et al. 2005;Miwa et al. 2010; Tsuchiya
et al. 1992)
Caffeine 1.2–1.5 g/m2/day for
3 days
G2/M checkpoint arrest (Kawabe 2004; Sabisz and Skladanowski 2008;
Zhou et al. 2000).
Diuretics Diuretics (Davis and Shock Theophylline 480 mg antagonism of adenosine receptors (Knight, Bowmer, and Yates 1993;
Rieg et al. 2005; Wilcox et al. 1999)
1949; Maughan and Griffin 2003) Caffeine >250–300 mg phosphodiesterase inhibition (Coulson and Scheinman 1989;
Fredholm, Hedqvist, and Vernet 1978)
Analgesic Analgesic adjuvant (Derry et al. 2014) Caffeine >100 mg maybe antagonism of adenosine receptors (Derry et al. 2014)
Post-lumbar puncture headache (Ragab
and Facharzt 2014)
Caffeine 500 mg antagonism of adenosine receptors (Ragab and Facharzt 2014)
Figure 5. Impact and advantages of methylxanthines in human health.
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be premature and even controversial. In another recent
review (Brent, Christian, and Diener 2011), the authors
claim that animal studies reporting methylxanthine (in this
case caffeine) detrimental effects on prenatal development
employ concentrations that will not be achieved by human
daily consumption. Thus, the authors concluded that nor-
mal human exposure should not impact spontaneous abor-
tion or normal fetal growth.
6. Conclusions
The methylxanthine historical importance in medicine was dis-
cussed throughout this paper. Established (and other now
obsolete) therapeutic uses (Table 4) remain under debate while
other contexts where methylxanthines may have pharmacologi-
cal interest were also unveiled. In fact, despite all the contexts
positively impacted by methylxanthines listed before, others
are emerging. However, given the scarce amount of studies
available at this point, they did not justify an entire section yet.
That is the case of hepatic (cholestatic liver injury and hepatitis
C), kidney (of uric acid nephrolithiasis) and ocular (myopia)
scopes.
Over the last decades, a great effort was made in order to
understand the molecular mechanisms underlying methylxan-
thine detrimental or beneficial effects, and even those that
motivate our craving for products rich in these compounds.
However, what seems crucial to highlight from the research
conducted so far, is the inherent potential that methylxanthines
carry to meaningfully impact modern biomedical research.
Despite the previously listed detrimental effects attributed to
the consumption of methylxanthines, if we weigh them against
the beneficial effects also aforementioned (Fig. 5), we would
probably reckon that health advantages outweigh potential
harms, and we would tend to quickly encourage a moderate
tea, coffee, or chocolate consumption. However, a more pro-
longed and thoughtful appreciation would compel us to be
more careful, although we would probably still lobby for it. The
problem is that, although “moderate consumption” should not
be detrimental, what “moderate consumption” really means is
not always available in a simple, accessible and quantified man-
ner. And that should be a difficult task, taking into account all
the idiosyncrasies involved that may impact the personal toler-
ance, and many other variables like interaction with other
drugs, the specificity of disease contexts, and even environmen-
tal constraints. It seems evident that methylxanthines can be
helpful in a variety of ways. Now, researchers will have to figure
out how to potentiate those inherent virtues. If widespread
methylxanthines use targeting pandemic diseases can be
approved and regulated by official agencies, we will secure fairly
inexpensive, readily-obtainable resources that may help us raise
general well-being, and that may translate into efficacious pre-
vention strategies to several disease-associated conditions.
Anyway, given all the promise attributed to these compounds,
additional research on methylxanthines seems completely justi-
fied. New studies should be envisioned, maybe using dietary-rele-
vant doses, since many experimental studies are conducted with
physiologically irrelevant concentrations. Although these studies
may help shedding some light to mechanistic questions, extrapo-
lation will always be difficult and questionable. Although there
may be constraints, well-designed epidemiologic trials encom-
passing a more precise clarification of dose–response relation-
ships would permit better comparison with observational data
and posterior translation into public health recommendations
and dietary guidelines. It would also be useful if these studies
could find ways to isolate the influence of methylxanthines in
drinks/foods from that of other components. In the case of caf-
feine, for instance, making outcome associations with caffeinated
or decaffeinated coffee consumption is a way of distinguishing
the effects on which this methylxanthine had indeed an impact.
Finally, with the increasingly easier access to state of the art pro-
cedures and equipment, like those involved in neuroimaging
techniques, it should be expectable that substantial breakthroughs
may be propitiated regarding the clarification of the mechanisms
underlying the neuroprotective (or detrimental) effects of methyl-
xanthine consumption.
While the doses attained physiologically by regular con-
sumption appear to be safe, methylxanthine pharmacological
concentrations may induce undesirable side-effects. Therefore,
there is a margin to architect new, more efficient and less harm-
ful molecular formulations based on methylxanthine structure.
Structure-activity approaches may help generate novel selective
cost-effective drugs displaying enhanced impact on specific
human conditions, while encompassing more manageable toxic
effects. This was already done to some extent in some specific
contexts. Putative synergistic effects of methylxanthines in
therapeutic cocktails may as well be a pertinent approach, and
such approach should indeed justify some meaningful research.
A more generalized and reasoned awareness of the beneficial
actions of methylxanthine may pave the way for the emergence
of new optimized cooperative therapy agents, but also of inno-
vative functional foods. In fact, cocoa manufacturers are mak-
ing experiments in production in order to provide new
functional cocoa products which are enriched in specific bioac-
tive components (polyphenols, methylxanthines or dietary
fiber), with reduced energy content (fat and sugar). This may
be a prolific area of research, with a great commercial interest.
As discussed before, both methylxanthine-containing func-
tional foods and novel derivatives would have a wide range of
possible physiologic targets susceptible of being modulated,
hopefully with relevant therapeutic outcomes. Moreover, other
areas are emerging where methylxanthines may assume addi-
tional relevance. That is the case of cosmetology and dermatol-
ogy (where caffeine is already used in anti-cellulite creams),
taking advantage of caffeine high biological activity and ability
to penetrate the skin barrier. That is also the case of possible
anti-inflammatory therapeutic applications of novel methyl-
xanthine derivatives (acting as mammalian chitinase inhibi-
tors). Anyway, there is still a lot to figure out until we make the
most of the promise raised by methylxanthine biochemistry.
Luckily enough, we do have coffee, and tea, and even chocolate,
to help us while paving the rest of the way.
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